Shawn D. Doran

1.4k citations

20 papers · 747 indexed · h-index 16

Co-authors: Ernesto Callegari John P. Gibbs Cuiping Chen Angela C. Doran Stacey L. Becker Frederick Nelson Julie Cianfrogna Jianhua Liu
Topics: Peptidase Inhibition and Analysis (7 papers)Diabetes Treatment and Management (7 papers)Drug Transport and Resistance Mechanisms (5 papers)
Cited by: Cellular and Molecular Neuroscience Oncology Endocrinology, Diabetes and Metabolism
Journals: Nature Communications Journal of Medicinal Chemistry Journal of Pharmacology and Experimental Therapeutics
Partner nations: United States Sweden United Kingdom

In The Last Decade

Shawn D. Doran

20 papers receiving 718 citations

Peers

Countries citing papers authored by Shawn D. Doran

Since Specialization

Citations

This map shows the geographic impact of Shawn D. Doran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shawn D. Doran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shawn D. Doran more than expected).

Fields of papers citing papers by Shawn D. Doran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shawn D. Doran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shawn D. Doran. The network helps show where Shawn D. Doran may publish in the future.

Co-authorship network of co-authors of Shawn D. Doran

This figure shows the co-authorship network connecting the top 25 collaborators of Shawn D. Doran. A scholar is included among the top collaborators of Shawn D. Doran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shawn D. Doran. Shawn D. Doran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Late-Stage Microsomal Oxidation Reduces Drug–Drug Interaction and Identifies Phosphodiesterase 2A Inhibitor PF-06815189 2018 ·ACS Medicinal Chemistry Letters ·Antonia F. Stepan,Tuan P. Tran,Christopher J. Helal,Maria S. Brown,Cheng Chang,Rebecca E. O’Connor,Michael De Vivo,Shawn D. Doran,Ethan L. Fisher,Stephen Jenkinson,David A. Karanian,Bethany L. Kormos,Raman Sharma,Gregory S. Walker,(unknown),(unknown),Michael A. Brodney,Travis T. Wager,Patrick R. Verhoest,R. Scott Obach	25
2	Quantitative Analysis of ¹⁸F-PF-06684511, a Novel PET Radioligand for Selective β-Secretase 1 Imaging, in Nonhuman Primate Brain 2018 ·Journal of Nuclear Medicine ·Akihiro Takano,Laigao Chen,Sangram Nag,Michael A. Brodney,Ryosuke Arakawa,Cheng Chang,Nahid Amini,Shawn D. Doran,Jason K. Dutra,Timothy J. McCarthy,Charles E. Nolan,Brian T. O’Neill,Anabella Villalobos,Lei Zhang,Christer Halldin	6
3	Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain 2018 ·Journal of Medicinal Chemistry ·Lei Zhang,Laigao Chen,Jason K. Dutra,Elizabeth Beck,Sangram Nag,Akihiro Takano,Nahid Amini,Ryosuke Arakawa,Michael A. Brodney,Leanne M. Buzon,Shawn D. Doran,Lorraine F. Lanyon,Timothy J. McCarthy,Kelly R. Bales,Charles E. Nolan,Brian T. O’Neill,Klaas Schildknegt,Christer Halldin,Anabella Villalobos	15
4	Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors 2016 ·Nature Communications ·Andrea M. Zuhl,Charles E. Nolan,Michael A. Brodney,Sherry Niessen,Kevin Atchison,Christopher Houle,David A. Karanian,Claude Ambroise,Jeffrey W. Brulet,Elizabeth M. Beck,Shawn D. Doran,Brian T. O’Neill,Christopher W. am Ende,Cheng Chang,Kieran F. Geoghegan,Graham M. West,Joshua C. Judkins,Xinjun Hou,David Riddell,Douglas S. Johnson	59
5	Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes 2014 ·Journal of Medicinal Chemistry ·David A. Griffith,Daniel W. Kung,William P. Esler,Paul A. Amor,Scott W. Bagley,Carine Beysen,Santos Carvajal‐Gonzalez,Shawn D. Doran,Chris Limberakis,Alan M. Mathiowetz,(unknown),David A. Price,Éric Ravussin,Gabriele E. Sonnenberg,(unknown),Laurel J. Sweet,Scott Turner,F.F. Vajdos	60
6	Metabolism, Excretion, and Pharmacokinetics of ((3,3-Difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a Dipeptidyl Peptidase Inhibitor, in Rat, Dog and Human 2012 ·Drug Metabolism and Disposition ·Raman Sharma,Hao Sun,David W. Piotrowski,Tim F. Ryder,Shawn D. Doran,Haiqing Dai,Chandra Prakash	24
7	Discovery of triazolopyrimidine-based PDE8B inhibitors: Exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes 2012 ·Bioorganic & Medicinal Chemistry Letters ·Michael P. DeNinno,Stephen W. Wright,John B. Etienne,(unknown),Benjamin N. Rocke,Jeffrey W. Corbett,Daniel W. Kung,Kenneth J. DiRico,Kim Andrews,(unknown),Janice C. Parker,William P. Esler,(unknown),(unknown),Karen L. Houseknecht,Shawn D. Doran	22
8	1-((3S,4S)-4-Amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes 2011 ·Bioorganic & Medicinal Chemistry Letters ·Kim Andrews,David A. Beebe,John W. Benbow,(unknown),Shawn D. Doran,Hui Yu,Shenping Liu,R. Kirk McPherson,Constantin Neagu,Janice C. Parker,David W. Piotrowski,(unknown),Judith L. Treadway,(unknown),William J. Zembrowski	16
9	1,5-Substituted nipecotic amides: Selective PDE8 inhibitors displaying diastereomer-dependent microsomal stability 2011 ·Bioorganic & Medicinal Chemistry Letters ·Michael P. DeNinno,Stephen W. Wright,Michael Visser,John B. Etienne,Dianna E. Moore,(unknown),Benjamin N. Rocke,(unknown),(unknown),(unknown),Brian P. Boscoe,(unknown),Shawn D. Doran,Karen L. Houseknecht	22
10	Discovery of CP-866,087, a mu opioid receptor antagonist for the treatment of alcohol abuse and dependence 2011 ·MedChemComm ·Stanton F. McHardy,Steven D. Heck,Sara Guediche,(unknown),Martin P. Allen,Meihua Tu,Dianne K. Bryce,Anne W. Schmidt,Michelle Vanase‐Frawley,Ernesto Callegari,Shawn D. Doran,Nicholas J. Grahame,Stafford McLean,Spiros Liras	20
11	Synthesis and SAR of 1,2,3,4-tetrahydroisoquinolin-1-ones as novel G-protein-coupled receptor 40 (GPR40) antagonists 2009 ·Bioorganic & Medicinal Chemistry Letters ·Paul S. Humphries,John W. Benbow,Paul D. Bonin,(unknown),Shawn D. Doran,Richard K. Frisbie,David W. Piotrowski,(unknown),Bruce M. Bechle,Edward L. Conn,Kenneth J. DiRico,Robert M. Oliver,Walter C. Soeller,(unknown),Xiaojing Yang	47
12	(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: A potent, selective, orally active dipeptidyl peptidase IV inhibitor 2009 ·Bioorganic & Medicinal Chemistry Letters ·Mark Ammirati,Kim Andrews,(unknown),(unknown),Dennis E. Danley,Shawn D. Doran,Bernard Hulin,Shenping Liu,R. Kirk McPherson,Stephen Orena,Janice C. Parker,Jana Polívková,Xiayang Qiu,(unknown),Judith L. Treadway,Maria A. VanVolkenburg,(unknown),David W. Piotrowski	33
13	Piperidinyl-2-phenethylamino inhibitors of DPP-IV for the treatment of Type 2 diabetes 2009 ·Bioorganic & Medicinal Chemistry Letters ·John W. Benbow,(unknown),Jiri Aubrecht,David A. Beebe,(unknown),Shawn D. Doran,(unknown),Hui Yu,(unknown),Janice C. Parker,Judith L. Treadway,(unknown),William J. Zembrowski	6
14	(3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: Synthesis, in vitro, in vivo, and X-ray crystallographic characterization 2007 ·Bioorganic & Medicinal Chemistry Letters ·Stephen W. Wright,Mark Ammirati,Kim Andrews,(unknown),Dennis E. Danley,Shawn D. Doran,Jay S. Lillquist,Shenping Liu,Lester D. McClure,R. Kirk McPherson,(unknown),Stephen Orena,Janice C. Parker,Benjamin N. Rocke,Walter C. Soeller,(unknown),Judith L. Treadway,Maria A. VanVolkenburg,(unknown),Eric Cox	13
15	Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·Jeffrey W. Corbett,Kenneth J. DiRico,(unknown),Brian P. Boscoe,Shawn D. Doran,(unknown),Xiayang Qiu,Mark Ammirati,Maria A. VanVolkenburg,R. Kirk McPherson,Jeremy C. Parker,Eric Cox	20
16	Evaluation of Cerebrospinal Fluid Concentration and Plasma Free Concentration As a Surrogate Measurement for Brain Free Concentration 2006 ·Drug Metabolism and Disposition ·Xingrong Liu,Bill J. Smith,Cuiping Chen,Ernesto Callegari,Stacey L. Becker,Xi Chen,Julie Cianfrogna,Angela C. Doran,Shawn D. Doran,John P. Gibbs,Natilie Hosea,Jianhua Liu,Frederick Nelson,(unknown),(unknown)	129
17	cis-2,5-Dicyanopyrrolidine Inhibitors of Dipeptidyl Peptidase IV: Synthesis and in Vitro, in Vivo, and X-ray Crystallographic Characterization 2006 ·Journal of Medicinal Chemistry ·Stephen W. Wright,Mark Ammirati,Kim Andrews,(unknown),Dennis E. Danley,Shawn D. Doran,Jay S. Lillquist,Lester D. McClure,R. Kirk McPherson,Stephen Orena,Janice C. Parker,Jana Polívková,Xiayang Qiu,Walter C. Soeller,(unknown),Judith L. Treadway,Maria A. VanVolkenburg,Hong Wang,(unknown),(unknown)	28
18	Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding 2005 ·Journal of Pharmacology and Experimental Therapeutics ·Xingrong Liu,Bill J. Smith,Cuiping Chen,Ernesto Callegari,Stacey L. Becker,Xi Chen,Julie Cianfrogna,Angela C. Doran,Shawn D. Doran,John P. Gibbs,Natilie Hosea,Jianhua Liu,Frederick Nelson,(unknown),(unknown)	136
19	A new class of selective and potent inhibitors of neuronal nitric oxide synthase 1999 ·Bioorganic & Medicinal Chemistry Letters ·John Lowe,(unknown),Robert A. Volkmann,Steven D. Heck,(unknown),Robert B. Nelson,Charles E. Nolan,Dane Liston,Karen Ward,Stevin H. Zorn,(unknown),(unknown),W. Stephen Faraci,(unknown),James Phinney Baxter,Shawn D. Doran,Martin Sanders,(unknown),Peter J. Whittle,Mark H. Stefaniak	15
20	Endogenous nitric oxide in expired air: Effects of acute exercise in humans 1994 ·Life Sciences ·John Anthony Bauer,Jeffrey A. Wald,Shawn D. Doran,David M. Soda	51

About Shawn D. Doran

Shawn D. Doran is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism and Pharmacology, having authored 20 papers that have together received 747 indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (7 papers), Diabetes Treatment and Management (7 papers) and Drug Transport and Resistance Mechanisms (5 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (153 citations), Oncology (213 citations) and Endocrinology, Diabetes and Metabolism (106 citations). Shawn D. Doran has collaborated with scholars based in United States, Sweden and United Kingdom. Frequent co-authors include Ernesto Callegari, John P. Gibbs, Cuiping Chen, Angela C. Doran, Stacey L. Becker, Frederick Nelson, Julie Cianfrogna, Jianhua Liu, Bill J. Smith and Natilie Hosea. Their work appears in journals such as Nature Communications, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact